Sports Nutrition Benefits of Weizmannia Coagulans BC99

NCT07325409 | Completed

• 1 other identifier: WK20251225
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the clinical efficacy of Weizmannia coagulans BC99 in young Chinese patients with exercise-induced muscle damage compared with placebo, and to explore its effects on inflammatory responses and intestinal microbiota.

Conditions

College Students of the School of Physical Education

Outcome Measures

Primary Outcomes (1)

• Pain evaluation

  Visual analog scale (VAS) was used for assessing the pain level of muscle, ranging from 0 to 10 point (0 means no pain; 10 represent worst imaginable pain). VAS scores were recorded at 24h, 48h and 72h after the intense exercise work stress.

  12 weeks

Secondary Outcomes (2)

• Cortisol in plasma

  12 weeks

• Peptide YY in plasma

  12 weeks

Study Arms (2)

Placebo group

PLACEBO COMPARATOR

3g dose of milk protein concentrate/pack, 8 packs per day

Dietary Supplement: Placebo

BC99 group

EXPERIMENTAL

3g dose of milk protein concentrate with 6×109 Colony Forming Unit (CFU) W. coagulans BC99/pack, 8 packs per day

Dietary Supplement: BC99

Interventions

Placebo DIETARY_SUPPLEMENT

The experimental phase of this study lasts 12 weeks and each participant will have 3 visits (week 0, week 6, week 12)

Placebo group

BC99 DIETARY_SUPPLEMENT

The experimental phase of this study lasts 12 weeks and each participant will have 3 visits (week 0, week 6, week 12)

BC99 group

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adults aged 19-35 years, with no restriction on sex;
• Physically active individuals with regular daily exercise training intensity and duration;
• No history of allergy to protein products;
• Body weight ≥50 kg for male subjects and ≥45 kg for female subjects; body mass index (BMI), calculated as weight (kg) divided by height squared (m²), within the range of 19.0-24.0 kg/m²;
• No history of cardiovascular or cerebrovascular diseases, hypertension, diabetes, hepatic or renal dysfunction, or other underlying diseases or metabolic disorders;
• Willingness to comply with the study protocol and study restrictions, and voluntary provision of written informed consent to participate in the study.

You may not qualify if:

• History of allergic constitution or immunodeficiency;
• Blood donation or significant blood loss (≥200 mL) within 3 months prior to administration of the investigational product;
• Presence of severe diseases of major organs, including the cardiovascular system, lungs, liver, or kidneys, as well as diabetes mellitus, severe thyroid disorders, metabolic diseases, malignant tumors, or severe immune system diseases;
• Use of medications affecting the intestinal microbiota (including antibiotics, microecological preparations, intestinal mucosal protectants, traditional Chinese medicines, etc.) for more than one consecutive week within 1 month prior to screening;
• Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in the study.

Sponsors & Collaborators

• Wecare Probiotics Co., Ltd.: lead

Study Sites (1)

Wu Ying

Luoyang, Henan, 471000, China

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 24, 2025
• First Posted: January 8, 2026
• Study Start: November 1, 2023
• Primary Completion: March 10, 2024
• Study Completion: March 28, 2024
• Last Updated: January 8, 2026

Record last verified: 2025-12

Locations

CN (1)